Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GRI Bio, Inc.GRI · Entity 8336 | Chief Financial Officer | September 18, 2025 | September 22, 2025 |
| WINDTREE THERAPEUTICS INC /DE/WINT · Entity 8761 | Director | January 08, 2025 | January 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GRI Bio, Inc.
Report date September 18, 2025 · Filed September 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2035-09-18 | Direct | 43,222 |
Reported balance
After 2025-09-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-18 · Grant · Acquired 43,222 · Balance 43,222 F1: Options to purchase 29,923 shares vested in full upon the date of grant and options to purchase 13,299 shares will vest in 12 substantially equal quarterly installments such that the stock option is fully vested on the third anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 29,923 shares vested in full upon the date of grant and options to purchase 13,299 shares will vest in 12 substantially equal quarterly installments such that the stock option is fully vested on the third anniversary of the date of grant.
WINDTREE THERAPEUTICS INC /DE/
Report date January 08, 2025 · Filed January 14, 2025
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2025 Filed Sep 22, 2025 16:06 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 43,222 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001398278-25-000004 · wk-form4_1758571567.xml · derivative · entry 1 Kelly Leanne · CIK 0001398278 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,222 Underlying: Common Stock · 43,222 shares Expires 2035-09-18 F1 · derivative.exercise_date: Options to purchase 29,923 shares vested in full upon the date of grant and options to purchase 13,299 shares will vest in 12 substantially equal quarterly installments such that the stock option is fully vested on the third anniversary of the date of grant. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 08:24 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 11,854 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001824293-25-000138 · wk-form4_1756297480.xml · derivative · entry 1 Kelly Leanne · CIK 0001398278 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,854 Underlying: Common Stock · 11,854 shares Expires 2035-08-26 F1 · derivative.exercise_date: Options to purchase 7,424 shares vested in full upon the date of grant and options to purchase 4,430 shares will vest in 12 substantially equal quarterly installments such that the stock option is fully vested on the third anniversary of the date of grant. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 17:58 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 43,319 | $0.69 Strike: $0.69 | $29,703.84 |
DisclosureSEC source: 0001824293-25-000035 · wk-form4_1737759502.xml · derivative · entry 1 Kelly Leanne · CIK 0001398278 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,319 Underlying: Common Stock · 43,319 shares Expires 2035-01-23 Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 16:08 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 83,333 | $1.52 Strike: $1.52 | $126,666.16 |
DisclosureSEC source: 0001824293-23-000163 · wk-form4_1695758927.xml · derivative · entry 1 Kelly Leanne · CIK 0001398278 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires 2033-09-22 F1 · derivative.exercise_date: Vests as to 25% of the underlying shares of common stock on the first annual anniversary of the date of grant, then in 36 equal monthly installments such that the stock option is fully vested on the fourth annual anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Mar 1, 2022 17:03 UTC | GRI Bio, Inc. VLON · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $5.63 Strike: $5.63 | $281,500.00 |
DisclosureSEC source: 0001824293-22-000010 · wf-form4_164617217734478.xml · derivative · entry 1 Kelly Leanne M. · CIK 0001398278 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-02-15 F1 · date: Reported late due to administrative error. F2 · derivative.exercise_date: Vests as to 25% of the underlying shares of common stock on the first annual anniversary of the date of grant, then in 12 equal quarterly installments such that the stock option is fully vested on the fourth annual anniversary of the date of grant. Read SEC document |
| June 04, 2021 Filed Jun 4, 2021 16:06 UTC | GRI Bio, Inc. VLON · Entity 8336 | PurchaseCommon Stock | 1,508 | $4.08 | $6,152.64 |
DisclosureSEC source: 0001104659-21-076998 · tm2118823d1_4.xml · nonDerivative · entry 3 Kelly Leanne M. · CIK 0001398278 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 16:06 UTC | GRI Bio, Inc. VLON · Entity 8336 | PurchaseCommon Stock | 1,085 | $4.05 | $4,394.25 |
DisclosureSEC source: 0001104659-21-076998 · tm2118823d1_4.xml · nonDerivative · entry 2 Kelly Leanne M. · CIK 0001398278 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,742 Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 16:06 UTC | GRI Bio, Inc. VLON · Entity 8336 | PurchaseCommon Stock | 3,657 | $4.00 | $14,628.00 |
DisclosureSEC source: 0001104659-21-076998 · tm2118823d1_4.xml · nonDerivative · entry 1 Kelly Leanne M. · CIK 0001398278 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,657 Read SEC document |
| May 14, 2021 Filed May 18, 2021 16:07 UTC | GRI Bio, Inc. VLON · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001104659-21-068835 · tm2116776-4_4.xml · derivative · entry 1 Kelly Leanne M. · CIK 0001398278 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: Vests as to 25% of the underlying shares of common stock on the first annual anniversary of the date of grant, then in 12 equal quarterly installments such that the stock option is fully vested on the fourth annual anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.